

Xylocaine

Lidocaine hydrochloride

Jelly 2%

Composition

1g XYLOCAINE Jelly contains lidocaine hydrochloride 20 mg.

Pharmaceutical form

XYLOCAINE Jelly is a clear to almost clear, slightly coloured jelly. The vehicle of the active ingredient consists of water thickened with hydroxypropyl methylcellulose. Jelly syringes are free from preservative. Jelly in tubes contains methyl parahydroxybenzoate and propyl parahydroxybenzoate.

Pharmacological properties

Pharmacotherapeutic group: Local anaesthetic, ATC Code: N01BB02.

XYLOCAINE Jelly 2% provides prompt and profound anaesthesia of mucous membranes and lubrications, which reduces friction. Its water-miscible base, characterized by high viscosity and low surface tension, brings the anaesthetic into intimate and prolonged contact with the tissue giving effective anaesthesia of long duration (approx. 20-30 min). Anaesthesia usually occurs rapidly (within 5 min. depending upon the area of application).

Lidocaine like other local anaesthetics, causes a reversible blockade of impulse propagations along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide type are thought to act within the sodium channels of the nerve membrane.

Local anaesthetic drugs may also have similar effects on excitable membranes in the brain and myocardium. If excessive amounts of drug reach the systemic circulation rapidly, symptoms and sign of toxicity will appear, emanating from the central nervous and cardiovascular systems.

Central nervous system toxicity usually precedes the cardiovascular effects as it occurs at lower plasma concentrations. Direct effects of local anaesthetics on the heart include slow conduction, negative inotropism and possibly cardiac arrest.

Lidocaine is absorbed following topical administration to mucous membranes, its rate and extent of absorption being dependent upon concentration and the total dose administered, the specific site of application and the duration of exposure. In general, the rate of absorption of local anaesthetic agent following topical application is most rapid after intratracheal and bronchial administration. Lidocaine is also well-absorbed from the gastrointestinal tract, although little intact drug appears in the circulation because of rapid biotransformation in the liver.

Normally about 65% of the lidocaine is bound to plasma proteins. Amide local anaesthetics are mainly bound to alpha-1-acid glycoprotein but also to albumin. Lidocaine crosses the blood brain and placental barriers, presumably by passive diffusion.

The main elimination pathway of lidocaine is by liver metabolism. The primary route of lidocaine in human is N-dealkylation to monoethylglycine xylidine (MEGX), followed by hydrolysis to 2,6-xylidine and hydroxylation to 4-hydroxy-2, 6-xylidine. MEGX can also be further dealkylated to glycine xylidine (GX). The pharmacological / toxicological actions of MEGX and GX are similar to, but less potent than, those of lidocaine. GX has a longer half-time (about 10 hr) than lidocaine and may be accumulated during long-term administration.

Approximately 90% of the lidocaine administered intravenously is excreted in the form of various metabolites and less than 10% is excreted unchanged in the urine. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-xylidine, accounting for about 70-80% of the dose excreted in the urine.

The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2.0 hours. Because of the rapid rate at which lidocaine is metabolised, any conditions that affects liver function may alter lidocaine kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulations of metabolites.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 µg free base per ml.

Preclinical safety data

In animal studies the toxicity noted after high doses of lidocaine consisted of effects on the central nervous and cardiovascular systems. No drug related adverse effects were seen in reproduction toxicity studies, neither did lidocaine show a mutagenic potential in either in vitro or in vivo mutagenicity tests. Cancer studies have not been performed with lidocaine, due to the area and duration of therapeutic use for this drug.

Genotoxicity tests with lidocaine showed no evidence of mutagenic potential. A metabolite of lidocaine, 2,6-xylidine, showed weak evidence of activity in some genotoxicity tests. The metabolite 2,6-xylidine has been shown to have carcinogenicity potential in preclinical toxicological studies evaluating chronic exposure. Risk assessments comparing the calculated maximum human exposure from intermittent use of lidocaine, with the exposure used in preclinical studies, indicate a wide margin of safety for clinical use.

Therapeutic Indications

XYLOCAINE Jelly is indicated as a surface anaesthetic and lubricant for:

- The male and female urethra during cystoscopy, catheterization, explorations by sound and other endourethral procedures.
- Nasal and pharyngeal cavities in endoscopic procedures such as gastroscopy and bronchoscopy.
- During proctoscopy and rectoscopy.
- Tracheal intubations.

Posology and method of administration

XYLOCAINE Jelly 2% provides prompt and profound anaesthesia of mucous membranes, giving effective anaesthesia of long duration (approx. 20-30 min). Anaesthesia usually occurs rapidly (within 5 min. depending upon the areas of application).

As with any local anaesthetic, the safety and effectiveness of lidocaine depends on the proper dosage, the correct technique, adequate precautions and readiness for emergencies.

The following dosage recommendations should be regarded as a guide. The clinician's experience and knowledge of the patient's physical status are of importance in calculating the required dose.

Absorption from mucus membranes is variable but especially high from the bronchial tree. The absorption of lidocaine jelly from the nasopharynx is usually lower than with other lidocaine products. Blood concentrations of lidocaine after instillation of the jelly in intact urethra and bladder in doses up to 800 mg are fairly low and below toxic limits.

Debilitated or elderly patients, children, acutely ill patients or patients with sepsis should be given doses commensurate with their age and physical condition.

The dose of topical XYLOCAINE should be taken into consideration in estimating the total dose of XYLOCAINE if parenteral XYLOCAINE is to be administered concomitantly.

Surface urethral anaesthesia, Adult:

Males: for adequate analgesia in males 20 ml (= 400 mg lidocaine hydrochloride) jelly is required. The jelly is instilled slowly until the patient has a feeling of tension or until almost half the tube (10 ml = 200 mg lidocaine hydrochloride) has been emptied. A penile clamp is then applied for several minutes at the corona, after which the rest of the jelly is instilled.

When anaesthesia is especially important, e.g. during sounding or cystoscopy, a larger quantity of jelly (e.g. 30-40 ml) may be instilled in 3-4 portions and allowed to act for 10 minutes before insertion of the instrument. The jelly instilled into the bladder is also effective for procedures in this region.

Females: Instil 5 to 10 ml in small portions to fill the whole urethra. In order to obtain adequate anaesthesia, several minutes should be allowed prior to performing urological procedures.

Endoscopy

Instillation of 10-20 ml into the appropriate body cavity is recommended for adequate analgesia and a small amount should be applied to lubricate the endoscope. The total dose of lidocaine should not exceed 400 mg.

Proctoscopy and rectoscopy

Up to 20 ml can be used for anal and rectal procedures. The total dose should not exceed 400 mg lidocaine.

Lubrication for endotracheal intubation

About 2 ml applied to the surface of the tube just prior to insertion. Care should be taken to avoid introducing the product into the lumen of the tube.

Special Warnings and Special Precaution for Use

Excessive doses or short intervals between doses may result in high plasma levels and serious adverse effects. Patients should be instructed to adhere strictly to the recommended dosage (the management of serious adverse reactions may require the use of resuscitative equipment, oxygen and other resuscitative drugs) (see *Overdose*).

Absorption from mucous membranes is variable but is especially high from the bronchial tree. Such applications may therefore result in rapidly rising or excessive plasma concentrations, with an increase risk for toxic symptoms, such as convulsions.

The absorption of lidocaine jelly from the nasopharynx is variable but usually lower than with other lidocaine products. Following instillation in urethra and bladder, absorption is low. Lidocaine jelly should be used with caution in patients with traumatized mucosa and/or sepsis in the region of the proposed application.

The oropharyngeal use of topical anaesthetic agents may interfere with swallowing and thus enhance at the danger of aspiration. This is particularly important in children because of their frequency of eating. Numbness of the tongue or buccal mucosa may increase the danger of biting trauma.

When used for endotracheal tube lubrications, care should be taken to avoid introduction of the jelly into the lumen of the tube. The jelly may dry on the inner surface leaving a residue, which tends to clump with flexion, narrowing the lumen. There have been rare reports in which this residue has caused the lumen to occlude.

Patients being treated with class III antiarrhythmic drugs (e.g. amiodarone) should be closely supervised, and ECG monitoring considered, as the effects on the heart can be additive. If the dose of administration is likely to result in high blood levels, some patients require special attention to prevent potentially dangerous side effects:

- Patients with partial or complete heart block
- The elderly and patients in poor general health.
- Patients with advanced liver disease or severe renal dysfunction.
- Patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic function, severe shock.

Avoid contact with the eyes.

XYLOCAINE Jelly is probably porphyrinogenic and should only be prescribed to patients with acute porphyria if there are very strong reasons. Appropriate precautions should be taken for all porphyric patients.

Undesirable Effects

Local reactions

An increased incidence of postoperative “sore throat” has been reported following endotracheal tube lubrication with lidocaine jelly.

Allergic reactions

Allergic reactions (in most severe instances anaphylactic shock) to local anaesthetics of the amide type are rare (<1/1000). Other constituents of the jelly e.g. methyl parahydroxybenzoate (in tubes only) and propyl parahydroxybenzoate (in tubes only) may also cause this type of reaction.

Acute systemic toxicity

Lidocaine may have acute toxic effects if high systemic levels occur due to fast absorption or overdose (see *Pharmacological properties* and *Overdose*)

- Systemic adverse reactions are extremely rare and may result from high plasma levels due to excessive dosage or rapid absorption or from hypersensitivity, idiosyncrasy reduced tolerance on the part of the patient. Such reactions involve the central nervous system and/or the cardiovascular system.
- CNS reactions are excitatory and/or depressant and maybe characterized by nervousness, dizziness, convulsions, unconsciousness and possible respiratory arrest. The excitatory reactions may be very brief or may not occur at all, in which case the first manifestations of toxicity may be drowsiness, merging into unconsciousness and respiratory arrest.
- Cardiovascular reactions are depressant and may be characterized by hypotension, myocardial depression, bradycardia and possible cardiac arrest.

Contraindications

Hypersensitivity to local anaesthetics of the amide type or to any of the excipients

Hypersensitivity to methyl and/or propyl parahydroxybenzoate (methyl-/propyl paraben) or to their metabolite para amino benzoic acid (PABA). Formulations of lidocaine containing parabens should be avoided in patients allergic to ester local anaesthetics or their metabolite PABA.

Interaction with Other Medicinal Products and Other Forms of Interaction

Lidocaine should be used with caution in patients receiving agents structurally related to local anaesthetics, antiarrhythmic drugs such as tocainide since the toxic effects are additive.

Specific interaction studies with local anaesthetics and class III antiarrhythmic drugs have not been carried out, but caution should be observed.

Drugs that reduce the clearance of lidocaine (e.g. cimetidine or betablockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period. Such interactions should be of no clinical importance following short term treatment with lidocaine at recommended doses.

Pregnancy and Lactation

It is reasonable to assume that a large n of pregnant women and women of child bearing age have used lidocaine. No specific disturbances to the reproductive process have so far been reported, e.g. no increase incidence of malformations.

Like other local anaesthetics, lidocaine may enter the mother's milk, but in such small amounts that there is generally no risk of this affecting the neonate.

Effects on the Ability to Drive and Use Machines

Depending on the dose, local anaesthetics may have a very mild effect on mental function and may temporarily impair locomotion and coordination.

Overdose

Acute systemic toxicity

Toxic reactions originate mainly in the central nervous system and the cardiovascular system.

Central nervous system toxicity is a graded response, with symptoms and sign of escalating severity. The first symptoms are circumoral paraesthesia, numbness of the tongue, lightheadedness, hyperacusis and tinnitus. Visual disturbances and muscular tremors are more serious and precede the onset of generalized convulsions. Unconsciousness and grand mal convulsions may follow, which may last from a few seconds to several minutes. Hypoxia and hypercarbia occur rapidly following convulsions due to increased muscular activity, together with the interference with normal respiration. In severe cases apnoea may occur. Acidosis increase the toxic effects of local anaesthetics.

Recovery is due to redistribution and metabolism of the local anaesthetic drug from the central nervous system. Recovery may be rapid unless large amounts of the drug have been administered.

Cardiovascular effects are only seen in cases with high systemic concentrations. Severe hypotension, bradycardia, arrhythmia and cardiovascular collapse may be the result in such cases.

Cardiovascular toxic effects are generally preceded by sign of toxicity in the central nervous system, unless the patient is receiving a general anaesthetic or is heavily sedated with drugs such a benzodiazepine or barbiturate.

Treatment of acute toxicity

Should symptoms of systemic toxicity occur, the signs are anticipated to be similar in nature to those following the adminstation of local anaesethetics by other routes. Local anaesthetic toxicity is manifested by symptoms of nervous system excitation and, in severe cases, central nervous and cardiovascular depression.

Severe neurological symptoms (convulsions, CNS depression) must be treated symptomatically by respiratory support and the administration of anticonvulsive drugs.

If circulatory arrest should occur, immediate cardiopulmonary resuscitation should be instituted. Optimal oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance.

Presentation

Box of 10 jelly syringe, 10 gram

Special Precautions for Storage

Do not store above 25°C.

Do not freeze.

Shelf life

2 years

HARUS DENGAN RESEP DOKTER**Reg No.:**

XYLOCAINE Jelly 2%, Jelly syringe 10 gram

Reg. No.: DKI1909500328A1

Manufactured by:

Recipharm Karlskoga AB, Karlskoga, Sweden for Aspen Global Incorporated

Imported by:

PT Mitsubishi Tanabe Pharma Indonesia

Bandung, Indonesia

Date of revision

October 2022

Xylocaine trademark is owned by or licensed to the Aspen group of companies.

© 2022 Aspen group of companies or its licensor.

All rights reserved.